Capital Raise MoniesWhen commenters here proffer that LPD's CR "
...so maybe this CR is just working capital...", it defames the company and suggests that the BoD has issued a false and misleading CR prospectus.
The prospectus is over 50 pages and published in English, so it is understandable that posters with poor English skills are unable to read it, however 3.1 includes a table that shows where the money raised will be spent. Just 33% of the expected CR will be spent of working capital, with
63% directed to progressing the project.
It is clear that posters offering "facts" are from a playbook produced to further another agendum.
Read, learn, understand.
Company ComparisonsTo compare LPD to other companies with a low SP is a simplistic and naïve approach to company analysis and poor investment advice.
Investors may be better informed if they consider:
1. The
strategy of the company, which JW reminded them in the latest Crux panel discussion was unchanged since 2016;
2. The strength of the
management team, which has been significantly expanded with skilled and experienced senior managers over 2022; and
3. The
outlook for the company, which is successfully moving towards
a) the development of a lepidolite mine with 20+ years of resource (attractive to Communist Party-owned Sinomine);
b) scale-up of LPD's unique L-Max, LOH-Max and PCR-Max technology, which is desperately required by Chinese lepidolite processors;
c) the development of a non-China supply source for Cs;
d) creation of a global lepidolite market for future expansion and licensing of the x-Max processes.
Investor SentimentThe number of investors has increased by 87% over the past two years. This implies an increasing number of investors are confident in the fundamental analysis described above.
Despite the repetitious noise from false friends, the CR has closed and the expected release of the Quarterly Report on Monday may include some indication of the support received from 14,967 investors.
Success of the CR will result in expenditure of the items listed in the table above, including the completion of the legal DD required by US DFC prior to Karibib funding. As JW mentioned in the Crux panel discussion, DFC approval, together with the engineering and legal DD results, will provide a significant uplift in confidence for commercial lenders of the KIZAD chemical plant.
